NCT06007937 2026-02-05A Study of Lorlatinib in Combination With Ramucirumab in People With Lung CancerMemorial Sloan Kettering Cancer CenterPhase 1/2 Recruiting56 enrolled
NCT02564198 2021-08-17A Study of Ramucirumab (LY3009806) in Children With Refractory Solid TumorsEli Lilly and CompanyPhase 1 Completed29 enrolled 12 charts